<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[DECODR]]></title><description><![CDATA[DECODR]]></description><link>https://www.decodrinc.com/blog</link><generator>RSS for Node</generator><lastBuildDate>Wed, 15 Apr 2026 09:01:23 GMT</lastBuildDate><atom:link href="https://www.decodrinc.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[CRISPR Concerns Won't Spoil Its Promise—If We Use the Right Tools]]></title><description><![CDATA[Eric B.  Kmiec, PhD The recent approval  by the U.S. Food and Drug Administration (FDA) of Casgevy, a therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene editing to treat patients with sickle cell disease, is a watershed moment in the history of this nascent field. I have been involved in gene therapy research for decades. Like many of my peers, I am thrilled that with this incredible breakthrough, CRISPR may be, as one story in GEN noted , entering...]]></description><link>https://www.decodrinc.com/post/crispr-concerns-won-t-spoil-its-promise-if-we-use-the-right-tools</link><guid isPermaLink="false">69c5c562653657f03d60d3bc</guid><pubDate>Thu, 26 Mar 2026 23:54:22 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/11bbf712d7d34ce69ac5afafb3fea993.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Eric B. Kmiec</dc:creator></item></channel></rss>